In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 681 ( 2023-02)
Abstract:
Despite advances in therapeutics for rheumatoid arthritis, not all patients respond fully to treatment. Here, Biesemann et al . determined, using single-cell RNA sequencing data, that inhibiting tumor necrosis factor (TNF) and interleukin (IL)-6 in combination may improve efficacy over monotherapies. The authors found that treatment with a cocktail of monoclonal antibodies targeting TNF and IL-6 reduced disease severity in a murine arthritis model, prompting them to generate an anti-TNF/IL-6 bispecific nanobody. The nanobody compound, which blocked human TNF and IL-6, effectively inhibited disease-relevant pathways in vitro. Together, these data support further development of this TNF/IL-6 nanobody as a therapy for rheumatoid arthritis. —CM
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abq4419
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Bookmarklink